Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Phasebio Pharmaceuticals Inc (PHAS)

Phasebio Pharmaceuticals Inc (PHAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,124
  • Shares Outstanding, K 28,781
  • Annual Sales, $ 2,360 K
  • Annual Income, $ -39,250 K
  • 60-Month Beta 1.93
  • Price/Sales 50.47
  • Price/Cash Flow N/A
  • Price/Book 2.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.50
  • Number of Estimates 3
  • High Estimate -0.46
  • Low Estimate -0.53
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -51.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.92 +8.51%
on 08/03/20
5.66 -24.88%
on 07/17/20
-0.14 (-3.17%)
since 07/02/20
3-Month
3.76 +13.05%
on 05/04/20
6.85 -37.94%
on 05/28/20
+0.40 (+10.41%)
since 05/01/20
52-Week
2.60 +63.49%
on 03/18/20
9.82 -56.73%
on 08/28/19
-3.43 (-44.65%)
since 08/02/19

Most Recent Stories

More News
PhaseBio Initiates Phase II Study for Coronavirus Patients

PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.

BMRN : 120.54 (+0.61%)
BDSI : 4.35 (+3.82%)
EBS : 118.75 (+6.75%)
PHAS : 4.25 (+6.25%)
PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

--PB1046, a long-acting analog of vasoactive intestinal peptide (VIP), has the potential to modulate several proinflammatory cytokines that are believed to be key drivers of the inflammatory response to...

PHAS : 4.25 (+6.25%)
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

IRWD : 9.67 (+5.45%)
REGN : 642.84 (+1.70%)
GILD : 71.46 (+2.78%)
ABIO : 6.86 (-2.00%)
NTLA : 18.85 (+5.84%)
PHAS : 4.25 (+6.25%)
PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment

PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.

RHHBY : 44.0825 (+2.28%)
INCY : 100.59 (+1.85%)
NVS : 83.99 (+2.25%)
PHAS : 4.25 (+6.25%)
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

--"VANGARD" trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome

PHAS : 4.25 (+6.25%)
PHASEBIO PHARMA (PHAS) Reports Q1 Loss, Lags Revenue Estimates

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -26.83% and -14.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

PHAS : 4.25 (+6.25%)
PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported...

PHAS : 4.25 (+6.25%)
Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PHAS : 4.25 (+6.25%)
PhaseBio Pharmaceuticals, Inc. (PHAS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in PhaseBio Pharmaceuticals, Inc. (PHAS).

PHAS : 4.25 (+6.25%)
Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PHAS : 4.25 (+6.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade PHAS with:

Business Summary

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet...

See More

Key Turning Points

2nd Resistance Point 4.21
1st Resistance Point 4.10
Last Price 4.25
1st Support Level 3.94
2nd Support Level 3.88

See More

52-Week High 9.82
Fibonacci 61.8% 7.07
Fibonacci 50% 6.21
Fibonacci 38.2% 5.36
Last Price 4.25
52-Week Low 2.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar